| Literature DB >> 32461967 |
Konstantinos Anagnostakos1, Andreas Thiery1, Christof Meyer1, Ismail Sahan1.
Abstract
Little is known about patients that undergo presumed aseptic revision arthroplasty surgery of the hip and knee joint and having positive microbiological findings of the intraoperatively taken tissue samples. 228 "aseptic" operations were retrospectively analyzed from prospectively collected data with regard to the following parameters: demographic data; reasons for primary and revision surgery, respectively; time between primary and revision surgery; preoperative laboratory findings; microbiological and histopathological findings; type and length of systemic antibiotic therapy; clinical outcome; and follow-up. Identification of microorganisms was present in 8.8% of the cases (9.3% of the hip and 7.8% of the knee cases). Preoperatively, the median CRP value was 8.4 mg/l (normal values 0-5.0 mg/l) and the median WBC count 8,100 × 106/l (normal values 3, 700-10,100 × 106/l). The most common identified organism was methicillin-resistant Staphylococcus epidermidis in 30%, followed by viridans streptococci in 15% of the cases. In 7 cases, the microbiological findings were interpreted as a contamination, and no antibiotic therapy was administered. In the other cases, a systemic antibiotic therapy was applied for a time period between 2 weeks and 3 months. 68.4% of the patients did not have any infectious complications at a median follow-up of 20 (3-42) months. The present study indicates that more than 2/3 of the cases with positive microbiological findings at the site of presumed aseptic revision arthroplasty surgery of the hip and knee joint can be successfully treated conservatively and they do not require any further surgical therapy.Entities:
Mesh:
Year: 2020 PMID: 32461967 PMCID: PMC7232730 DOI: 10.1155/2020/2162136
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Demographic data of the patients.
| Patient | Gender | Age | Affected joint | Reason for primary surgery | Reason for revision surgery | Time between primary and revision surgery (months) |
|---|---|---|---|---|---|---|
| 1 | f | 79 | Hip | Periprosthetic fracture Vancouver type C after cemented hemiarthroplasty for femoral neck fracture | Stem loosening | 9 after periprosthetic fracture/17 after cemented hemiarthroplasty |
| 2 | m | 38 | Hip | Femoral head necrosis | Recurrent dislocations | 5 |
| 3 | m | 74 | Knee | Degenerative osteoarthritis | Secondary PCL instability | 5 |
| 4 | m | 86 | Hip | Acetabular revision surgery | Cup loosening | 52 |
| 5 | f | 62 | Hip | Degenerative osteoarthritis | Cup loosening | 128 |
| 6 | m | 48 | Hip | Posttraumatric osteoarthritis | Cup loosening | 44 |
| 7 | m | 78 | Knee | Degenerative osteoarthritis | Tibial component loosening | 132 |
| 8 | m | 57 | Hip | Periprosthetic fracture Vancouver type B2 after cementless total hip arthroplasty | Stem subsidence | 10 |
| 9 | f | 72 | Hip | Aseptic THA revision | Cup loosening | 85 |
| 10 | f | 52 | Knee | Aseptic TKA revision | Tibial component loosening | 70 |
| 11 | m | 62 | Hip | Degenerative osteoarthritis | Stem loosening | 108 |
| 12 | m | 60 | Knee | Degenerative osteoarthritis | Mediolateral instability | 100 |
| 13 | m | 78 | Knee | Degenerative osteoarthritis | Femoral component loosening | 92 |
| 14 | m | 82 | Hip | Septic two-stage revision | Stem loosening | 88 |
| 15 | m | 80 | Knee | Septic two-stage revision | Tibial component loosening | 10 |
| 16 | m | 73 | Hip | Degenerative osteoarthritis | Cup loosening | 252 |
| 17 | f | 83 | Hip | Degenerative osteoarthritis | Periprosthetic fracture Vancouver type B2 | 192 |
| 18 | f | 81 | Hip | Degenerative osteoarthritis | Cup loosening | 132 |
| 19 | m | 68 | Hip | Femoral neck fracture | Periprosthetic fracture Vancouver type B2 | 3 |
| 20 | f | 86 | Hip | Degenerative osteoarthritis | Stem loosening | 180 |
f: female; m: male; PCL: posterior cruciate ligament; THA: total hip arthroplasty; TKA: total knee arthroplasty.
Laboratory, microbiological, and histopathological findings at the site of presumed aseptic revision arthroplasty surgery of the hip and knee joint.
| Patient | Preop. CRP (mg/l) | Preop. WBC (×106/l) | Microbiological findings | No. of positive/No. of taken samples | Histopathological findings |
|---|---|---|---|---|---|
| 1 | 47.9 | 7,800 | MRSE | 1/3 | Type III |
| 2 | 8.5 | 10,400 | MRSE | 1/3 | Type I |
| 3 | 10.0 | 5,900 | MRSE | 2/3 | Type I |
| 4 | 5.5 | 14,900 | MRSE | 1/3 | Type I |
| 5 | 2.9 | 6,900 | CNS∗ | 1/3 | Type IV |
| 6 | 6.1 | 8,400 | Staphylococcus capitis | 1/3 | Type III |
| 7 | <2.0 | 6,800 | Viridans streptococci∗ | 1/5 | Type I |
| 8 | 10.6 | 5,200 | MRSE∗ | 1/1 | Type I |
| 9 | <2.0 | 4,900 | Gram-positive rods (coryneform) | 1/3 | Type I |
| 10 | 10.1 | 11,400 | Staphylococcus hominis∗ | 1/4 | Type I |
| 11 | 8.3 | 13,100 | MSSE | 1/3 | Type III |
| 12 | 4.8 | 10,800 | Viridans streptococci∗ | 1/3 | Type I |
| 13 | 6.8 | 9,200 | MRSE | 3/3 | Type I |
| 14 | 32.0 | 11,000 | Staphylococcus capitis∗ | 1/4 | Type I |
| 15 | 11.6 | 9,300 | Staphylococcus hominis | 2/3 | Type III |
| 16 | 42.2 | 7,200 | Escherichia coli | 1/3 | Type III |
| 17 | 12.6 | 7,700 | Citrobacter koseri | 2/3 | Type II |
| 18 | 4.2 | 5,300 | Cutibacterium acnes | 2/3 | Type I |
| 19 | 17.7 | 5,100 | Gram-negative rods (no specification) | 1/5 | Type I |
| 20 | 5.1 | 8,500 | Streptococcus oralis | 2/4 | Type III |
CRP: C-reactive protein; WBC: white blood cell; MRSE: methicillin-resistant Staphylococcus epidermidis; CNS: coagulase-negative staphylococci; MSSE: methicillin-susceptible Staphylococcus epidermidis; ∗only 1 colony.
Therapy details and outcome.
| Patient | Systemic antibiotic therapy | Infection persistence | Outcome | Follow-up (months) |
|---|---|---|---|---|
| 1 | Cefuroxime for 6 weeks | No | Intraop. decision for two-stage protocol, permanent Girdlestone | 42 |
| 2 | Linezolid for 2 weeks | Yes | Two-stage protocol after 1 year | 40/28 |
| 3 | None | Yes | Arthrofibrosis within 8 weeks, infection persistence; permanent spacer after 7 months | 39 |
| 4 | Ceftriaxone for 2 weeks | No | Revision surgery after 10 days due to prolonged drainage, negative microbiology, shoulder empyema after 9 days (E. cloacae), linezolid for 4 weeks | 31 |
| 5 | None | No | Uneventful course | 30 |
| 6 | Rifampicin+teicoplanin for 2 weeks | No | Uneventful course | 29 |
| 7 | Levofloxacin for 6 weeks | No | Intraop. decision for two-stage protocol, reimplantation after 7 weeks | 28 |
| 8 | None | No | Uneventful course | 25 |
| 9 | None | No | Uneventful course | 23 |
| 10 | None | No | Uneventful course | 20 |
| 11 | None | No | Uneventful course | 18 |
| 12 | Rifampicin+levofloxacin for 4 weeks | No | Uneventful course | 17 |
| 13 | Rifampicin+levofloxacin for 3 months | No | Uneventful course | 15 |
| 14 | None | No | Prosthesis dislocation after 1 week, open reduction | 14 |
| 15 | Rifampicin+teicoplanin for 4 weeks, followed by rifampicin+linezolid for 2 weeks | Yes | Two-stage protocol after 6 months | 3 |
| 16 | Rifampicin+levofloxacin for 6 weeks | Yes | Death due to cardiopulmonal decompensation after 6 weeks | n.r. |
| 17 | Meronem+ciprofloxacin for 6 weeks | Yes | Two-stage protocol after 2 weeks | 3 |
| 18 | Rifampicin+levofloxacin for 6 weeks | No | Uneventful course | 6 |
| 19 | Rifampicin+Meronem for 4 weeks | Yes | Revision due to stem subsidence after 10 weeks, identification of MSSE, conservative treatment | 4 |
| 20 | Rifampicin+levofloxacin for 6 weeks | No | Uneventful course | 3 |
n.r.: not relevant.